Cibus (CBUS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.3M

Revenue (quarter)

$994,000.00

Revenue growth (year over year)

+6.54%

Gross profit (trailing twelve months)

$4.3M

Gross margin

100.00%

Net income (trailing twelve months)

−$99.6M

Net income (quarter)

−$22.1M

Net income growth (year over year)

+16.62%

Net margin

−2291.65%

Return on equity

−225.93%

EPS (trailing twelve months)

−$1.51

Book value per share

$0.19

P/E (trailing twelve months)

—

Price to book

7.28

Debt to assets

95.28%

Payout ratio

—

Dividend yield

—

Company profile

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

• Is Cibus (CBUS) profitable?

  No. Cibus reported a net loss of $99.6M over the trailing twelve months.

• How much revenue does Cibus (CBUS) make?

  Cibus generated $4.3M in revenue over the trailing twelve months, up 6.54% year over year.

• How do I buy stock in Cibus (CBUS)?

  CBUS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.